ADC Therapeutics

ADC Therapeutics is a clinical-stage oncology drug development company focused on creating highly targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. The company's proprietary ADCs are developed using the latest generation pyrrolobenzodiazepine (PBD) dimer platform, which offers improved therapeutic indices compared to first-generation PBD ADCs. PBD dimers are highly potent toxins that effectively kill cancer cells and operate via a mechanism of action distinct from warheads commonly used in other ADCs. ADC Therapeutics has four key development pipelines: ADCT-402, ADCT-301, ADCT-602, and ADCT-601.